Clinical Trials
18
Active:0
Completed:9
Trial Phases
4 Phases
Phase 1:7
Phase 2:3
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (38.9%)Not Applicable
6 (33.3%)Phase 2
3 (16.7%)Phase 3
2 (11.1%)IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer
Phase 3
Suspended
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 200
- Registration Number
- NCT00316745
- Locations
- 🇯🇵
Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan
Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 40
- Registration Number
- NCT00209651
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
Phase 2
Suspended
- Conditions
- Gastric Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-02-02
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 40
- Registration Number
- NCT00209664
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-02-17
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 40
- Registration Number
- NCT00209612
- Locations
- 🇯🇵
・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan
Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Phase 1
Suspended
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 40
- Registration Number
- NCT00209677
- Locations
- 🇯🇵
Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan
- Prev
- 1
- 2
- 3
- Next
News
No news found